Suppliers / Dijia Pharmaceutical Group

Dijia Pharmaceutical Group

China Updated 9 July 2026

Dijia Pharmaceutical Group is an API manufacturer based in China. It holds one active US drug master file and 3 valid CEPs across a filed portfolio of 4 molecules.

1
active US DMFs
3
valid CEPs
2
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026.

Registered plants

Site FDA FEI
Weihai, China Not on file
China, China 3011998304

What they file, and where

Molecule Regulators Docs
Glipizide US FDA 1
Rivaroxaban EDQM 1
Solifenacin Succinate EDQM 1
Terazosin EDQM 1

Also appears on these molecule pages

Glipizide API Terazosin API Rivaroxaban API Solifenacin API

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 1 None

Comparing suppliers?

Choose your molecules and target markets. Dijia Pharmaceutical Group comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability